The Gross Law Firm notifies investors that a class action has commenced in the United States District Court for the Southern District of New York on behalf of shareholders of DexCom, Inc. who purchased Securities between July 26, 2024 and September 17, 2025.
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) DexCom had made material design changes to The Company’s glucose monitoring products, the G6 and G7, unauthorized by the U.S. Food and Drug Administration; (ii) the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (iii) accordingly, defendants’ purported enhancements to the G7, as well as the device’s reliability, accuracy, and functionality, were overstated; (iv) defendants downplayed the true scope and severity of the issues and health risks posed by adulterated G7 devices; (v) all the foregoing subjected DexCom to an increased risk of heightened regulatory scrutiny and enforcement action, as well as significant legal, reputational, and financial harm; and (vi) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.
Shareholders have until December 26, 2025 to request that the court appoint them lead plaintiff.
To receive more information, please fill out the form.
